Paul Sheehan

Executive Director, Head of U.S. REMS
Celgene Corporation
Paul Sheehan, BSc (Hons), CPHIMS is the Head of the Celgene U.S. REMS Department responsible for the design, implementation and maintenance of the REMS programs for REVLIMID, POMALYST and THALOMID. Paul has 18 years experience working in the pharmaceutical risk management industry, and previously was the head of global risk management operations at Pharmion, and a consultant at SI International who designed, developed and managed risk management programs for Roche, BMS, & GSK among others. Paul holds a BSc (Hons) Information Systems Management from Bournemouth University, England, and is completing his MS in Jurisprudence from Seton Hall University School of Law. Paul is a co-author of a number of articles about pharmaceutical risk management, presented at international conferences, and served as an expert advisor and presenter for multiple FDA advisory panels and public meetings about the subject.